<DOC>
	<DOCNO>NCT02829294</DOCNO>
	<brief_summary>This prospective , open-labeled clinical trial . Subjects qualify enrollment provide inform consent treat novel topical cerumen ( earwax ) removal product . The primary goal pilot study gain understanding safety efficacy novel product .</brief_summary>
	<brief_title>Evaluation Novel Product Removal Impacted Human Cerumen ( Earwax )</brief_title>
	<detailed_description>This single center , single-arm , open-label trial . Approximately 30 evaluable ear enrol least 50 % cerumen impaction . All ears/subjects receive least single dose ( approximately 1 - 2 mL ) test product apply topically study ear canal . The test product supply qualified compound pharmacy receive by-subject prescription investigator . The subject dose head tilt order keep test product ear canal 15 minute . At 5 10 minute , subject instruct move jaw ( side side ) time , manipulate/massage ear canal press jawbone ear lobe rotate motion 10 second , may aid distribution test product ear canal . Fifteen minute product instillation , remove subject tilt head disposable container catch solution . The ear canal irrigate ( low pressure ) warm water , evaluator try visualize tympanic membrane use otoscope ( lavage ) . The amount ( change area , volume depth ) tympanic membrane visualize categorization cerumen impaction ( accord 5 point scale ) primary efficacy parameter study . Efficacy also assess use subjective question ( improvement change symptom ) ask study staff document prior subject knowledge otoscope result ( visualization TP ) .</detailed_description>
	<criteria>1 . Males nonpregnant female â‰¥ 40 year age enrollment ; 2 . Presence excessive impact cerumen [ excessive impacted cerumen identify cause partial ( &gt; 50 % ) complete occlusion least one ear canal attempt visualize tympanic membrane ] ; 3 . Willingness participate study ; 4 . Mental aptitude provide verbal and/or write informed consent without aid another . 1 . Pregnant , breastfeeding , unwilling practice birth control participation study ( accustomed birth control continue include Visit 2 ) ; 2 . Presence tympanostomy tube time previous 12 month ; 3 . Presence nonintact tympanic membrane ( TM ) ; 4 . Presence know suspect ear infection ; 5 . Presence know suspected mastoiditis ; 6 . Use ototopical drug OTC product earwaxremoval product ( exception water physiologic saline ) precede 3 day ; 7 . Presence condition abnormality opinion Investigator would compromise safety patient quality data ( e.g . ear eczema seborrhea ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>